Compare ASH & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | IMNM |
|---|---|---|
| Founded | 1924 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2016 | 2020 |
| Metric | ASH | IMNM |
|---|---|---|
| Price | $53.03 | $19.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $65.57 | $32.80 |
| AVG Volume (30 Days) | 578.4K | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,824,000,000.00 | $6,941,000.00 |
| Revenue This Year | $2.52 | N/A |
| Revenue Next Year | $3.74 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $45.21 | $5.15 |
| 52 Week High | $65.65 | $27.65 |
| Indicator | ASH | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 36.87 |
| Support Level | $47.57 | $19.26 |
| Resistance Level | $54.56 | $22.57 |
| Average True Range (ATR) | 1.73 | 1.05 |
| MACD | 0.43 | -0.04 |
| Stochastic Oscillator | 64.92 | 1.41 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.